Analysts Offer Insights on Healthcare Companies: Organigram Global (OGI) and Spyre Therapeutics (SYRE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Organigram Global (OGI – Research Report) and Spyre Therapeutics (SYRE – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Organigram Global (OGI)
ATB Capital Markets analyst Frederico Gomes maintained a Buy rating on Organigram Global today and set a price target of C$3.50. The company’s shares closed last Thursday at $1.45.
According to TipRanks.com, Gomes is a 1-star analyst with an average return of
Organigram Global has an analyst consensus of Strong Buy, with a price target consensus of $2.69, an 88.1% upside from current levels. In a report issued on February 10, Alliance Global Partners also maintained a Buy rating on the stock with a C$4.00 price target.
See today’s best-performing stocks on TipRanks >>
Spyre Therapeutics (SYRE)
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Spyre Therapeutics, with a price target of $55.00. The company’s shares closed last Thursday at $37.81, close to its 52-week high of $40.84.
According to TipRanks.com, Slutsky is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spyre Therapeutics with a $58.71 average price target, representing a 60.1% upside. In a report released today, Citi also maintained a Buy rating on the stock with a $64.00 price target.
